A quantitative analysis of subjective, cognitive, and physiological manifestations of the acute tobacco abstinence syndrome.
BACKGROUND
Previous studies have documented the existence of signs and symptoms of the acute tobacco abstinence syndrome; however, less attention has been paid to quantifying the magnitude of these effects.


OBJECTIVE
The present study quantified the relative magnitude of subjective, cognitive, and physiological manifestations of acute tobacco abstinence.


METHODS
Smokers (N=203, ≥ 15 cig/day) attended two counterbalanced laboratory sessions, one following 12-h of abstinence and the other following ad-lib smoking. At both sessions, they completed an extensive battery of self-report measures (withdrawal, affect, hunger, craving, subjective attentional bias towards smoking cues), physiological assessments (heart rate, blood pressure, brain EEG), and cognitive performance tasks (psychomotor processing, sustained attention, objective attentional bias).


RESULTS
Abstinence effects were largest for craving, subjective attentional bias, negative affect, overall withdrawal severity, concentration difficulty, hunger, and heart rate. Effects were moderate for positive affect and EEG power. Effects were small, but reliable, for psychomotor speed, sustained attention, and somatic symptoms. Effects on performance-based indices of attentional bias towards smoking-related cues were small and reliable for some indices but not others. Effects were small and inconsistent for blood pressure and EEG frequency. Variation in internal consistency accounted for 33% of the variation in abstinence effect sizes across measures.


CONCLUSIONS
There was a wide range of effect sizes both across and within domains, indicating that the acute tobacco abstinence syndrome is not a monotonic phenomenon. These findings may be indicative of the relative magnitudes of signs and symptoms that the average smoker may exhibit during acute abstinence.
Leventhal
Adam M
AM
Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. adam.leventhal@usc.edu
Waters
Andrew J
AJ
Moolchan
Eric T
ET
Heishman
Stephen J
SJ
Pickworth
Wallace B
WB
D000328:Adult; D015142:Baltimore; D001794:Blood Pressure / Q000187:drug effects; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects*; D016540:Smoking Cessation / Q000523:psychology*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology / Q000523:psychology
Exp Clin Psychopharmacol. 2007 Feb;15(1):67-80
17295586
Psychol Addict Behav. 2003 Mar;17(1):66-72
12665083
Psychopharmacology (Berl). 2007 Nov;195(1):1-9
17634928
Exp Clin Psychopharmacol. 1999 Nov;7(4):354-61
10609970
Neuropsychopharmacology. 2001 Feb;24(2):97-129
11120394
J Consult Clin Psychol. 2006 Dec;74(6):1153-61
17154744
Psychopharmacology (Berl). 2006 Mar;184(3-4):619-27
16308727
Addiction. 2006 Dec;101(12):1822-32
17156182
Nicotine Tob Res. 2006 Apr;8(2):153-6
16766409
Nicotine Tob Res. 2008 Apr;10(4):643-51
18418787
Psychol Bull. 2006 May;132(3):443-76
16719569
Nicotine Tob Res. 2001 Feb;3(1):7-16
11260806
Exp Clin Psychopharmacol. 1999 Nov;7(4):427-43
10609977
J Psychiatr Res. 1982-1983;17(2):203-12
6764938
Exp Clin Psychopharmacol. 2007 Feb;15(1):21-36
17295582
Nicotine Tob Res. 1999 Mar;1(1):45-52
11072387
Addiction. 2001 Oct;96(10):1419-32
11571061
Psychopharmacology (Berl). 2006 Dec;189(3):355-67
17047930
Nicotine Tob Res. 1999;1 Suppl 2:S143-7; discussion S165-6
11768172
Brain Cogn. 2003 Oct;53(1):75-81
14572505
Psychopharmacology (Berl). 2007 Mar;190(4):457-67
17205318
Nicotine Tob Res. 2007 Mar;9(3):315-27
17365764
Arch Gen Psychiatry. 1986 Mar;43(3):289-94
3954551
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
3397865
J Pharmacol Exp Ther. 1989 Dec;251(3):976-82
2600826
Clin Psychol Rev. 2006 Mar;26(2):196-215
16352382
J Abnorm Psychol. 2006 Aug;115(3):454-66
16866586
Exp Clin Psychopharmacol. 2006 May;14(2):121-35
16756416
Addict Behav. 2007 Dec;32(12):2976-89
17624682
Psychopharmacology (Berl). 2006 Aug;187(3):385-96
16752139
J Abnorm Psychol. 2003 Feb;112(1):3-13
12653409
Psychopharmacology (Berl). 2000 Jan;148(1):33-40
10663415
Behav Pharmacol. 2004 Feb;15(1):29-36
15075624
Drug Alcohol Depend. 1989 Jun;23(3):259-66
2752917
Nicotine Tob Res. 2004 Aug;6(4):599-614
15370156
Psychol Addict Behav. 2007 Jun;21(2):127-37
17563132
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Psychol Rev. 2004 Jan;111(1):33-51
14756584
J Abnorm Psychol. 2008 Feb;117(1):94-105
18266488
Neuropsychopharmacology. 2008 Feb;33(3):588-98
17443125
Health Psychol. 2003 Jul;22(4):378-87
12940394
Exp Clin Psychopharmacol. 2008 Aug;16(4):301-312
18729684
Psychopharmacology (Berl). 1996 Sep;127(1):31-8
8880941
Pharmacol Biochem Behav. 2004 Jan;77(1):103-9
14724047
Psychopharmacology (Berl). 2006 Mar;184(3-4):637-44
16261317
Pharmacol Biochem Behav. 2002 Jun;72(3):707-16
12175468
Neurobehav Toxicol Teratol. 1985 Jul-Aug;7(4):415-8
3840579